Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20558581 | 0.88 | MEN1 (0.41) | HSD11B1KCNN4ARPYCR1SLC22A12 | |
| SCHEMBL29467226 | 0.87 | KCNN4 (0.48) | HSD11B1KCNN4ARPYCR1LMNA | |
| SCHEMBL5966718 | 0.87 | KCNN4 (0.48) | HSD11B1KCNN4ARPYCR1LMNA | |
| SCHEMBL117692 | 0.87 | KCNN4 (0.48) | HSD11B1KCNN4ARPYCR1LMNA | |
| Benzene SCHEMBL29136712 | 0.84 | KCNN4 (0.52) | HSD11B1KCNN4ARPYCR1LMNA | |
| SCHEMBL5607381 | 0.84 | KCNN4 (0.46) | HSD11B1KCNN4ARPYCR1LMNA | |
| Ammonia Solution, Strong SCHEMBL15562823 | 0.84 | KCNN4 (0.46) | HSD11B1KCNN4ARPYCR1LMNA | |
| SCHEMBL29057192 | 0.84 | KCNN4 (0.46) | HSD11B1KCNN4ARPYCR1LMNA | |
| SCHEMBL4463108 | 0.84 | KCNN4 (0.46) | HSD11B1KCNN4ARPYCR1LMNA | |
| SCHEMBL28034993 | 0.84 | KCNN4 (0.46) | HSD11B1KCNN4ARPYCR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104710355-B | The preparation method and purposes of diphenyl thiourea compounds and its salt of one class containing niacinamide building block | 烟台大学 | 2017-06-16 | — | — | CN | disclosed |
| CN-104045598-B | Thiourea compounds containing arylamine structure, and preparation method and application thereof | 烟台大学 | 2017-02-15 | — | — | CN | disclosed |
| CN-104892529-A | Thiourea compound containing quinazoline structure as well as preparation method and application of thiourea compound | UNIV YANTAI | 2015-09-09 | — | — | CN | disclosed |
| CN-104710355-A | Preparation method and application of diphenyl thiourea compound containing niacinamide building blocks and salt of diphenyl thiourea compound | UNIV YANTAI | 2015-06-17 | — | — | CN | disclosed |
| CN-104045598-A | Thiourea compounds containing arylamine structure, and preparation method and application thereof | UNIV YANTAI | 2014-09-17 | — | — | CN | disclosed |
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-1608369-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| EP-1618127-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005032548-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1499311-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | Chiron Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HSD11B1 2525/4885KCNN4 4297/4885AR 2574/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HSD11B1 2200/4885KCNN4 4024/4885AR 2123/4885 |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | HSD11B1 2525/4885KCNN4 4297/4885AR 2574/4885 |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | ICOS, CD14, LCP2 | HSD11B1 3535/4885KCNN4 3678/4885AR 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.